Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡Markus Cornberg, Heiner Wedemeyer, Stephanie Buchholz et al.|Journal of Hepatology|2019Cited by 364
Nomenclature of HBV core protein-targeting antiviralsFabien Zoulim, Harry L.A. Janssen, Adam Zlotnick et al.|Nature Reviews Gastroenterology & Hepatology|2022Cited by 67
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G. Peters, Oliver Lenz, Man‐Fung Yuen et al.|Clinical Infectious Diseases|2023Cited by 9